CRISPR Therapeutics, a Switzerland-based biopharmaceutical gene editing company, has announced it is building a new cell therapy manufacturing facility in Framingham.
The new facility will create 100 jobs, according to a release from the company based in Cambridge and Zug, Switzerland. The site will be used for clinical and commercial production of the company’s investigational cell therapies.
The facility will allow the company to accelerate its programs and scale up for commercial supply, according to CRISPR Therapeutics CEO Samarth Kulkarni.
“We are thankful for the support from the City of Framingham and the Commonwealth of Massachusetts, and we look forward to bringing our facility online rapidly,” Kulkarni said in a release.
The new facility is being designed to provide GMP (good manufacturing practice) manufacturing, according to the U.S. Food and Drug Administration and European Medicines Agency regulations and guidelines to support clinical supply and commercial product upon potential regulatory approval.
The company did not specify when the factory will open.
